The Modern Revival · Clinical renaissance
The Clinical Renaissance
1962–present
After decades of prohibition, psilocybin went back into the laboratory. From a 1962 chapel experiment to Phase 3 depression trials in the 2020s, this is the most rigorous — and most cautiously promising — chapter of the modern story.
From chapel to clinic
The clinical thread is the oldest continuous one in the modern story. It arguably begins in 1962, when Walter Pahnke’s Good Friday Experiment gave divinity students psilocybin or placebo in a Boston chapel and measured the results — an early, imperfect attempt to study mystical experience with scientific controls.1 Prohibition then closed the laboratory for a generation.
The reopening
Rigorous research resumed in 2006, when Roland Griffiths and colleagues at Johns Hopkins published a careful study of psilocybin and mystical-type experience.2 That paper is widely credited with restarting the field. Over the next fifteen years, trials at Hopkins, Imperial College London, NYU and elsewhere built a body of evidence for psilocybin-assisted therapy in depression, end-of-life distress, and addiction.
Where it stands in 2026
Momentum is real. Psilocybin programmes hold FDA Breakthrough Therapy designation, and in 2025–2026 COMPASS Pathways reported positive Phase 3 results for treatment-resistant depression, with a regulatory submission targeted for late 2026.3 But the honest headline is not yet approved: the science is the strongest it has ever been and still unfinished. Blinding is difficult, long-term outcomes are still accumulating, and clinical benefit is a different claim from the spiritual and traditional ones documented across this archive.
Why this is a Western chapter, not a universal one
Clinical psilocybin therapy is a distinctly modern, Western institutional form — protocols, dosing rooms, rating scales. It deserves to be documented with the same care as any tradition, and kept distinct from them: the Mazatec velada and a Phase 3 trial are both real, and they are not the same thing.
Footnotes
Historical record
- 1962
The Good Friday Experiment
Walter Pahnke's Marsh Chapel study tests psilocybin and mystical experience under Harvard supervision — early rigour, later criticised.
Later scholarly interpretation - 2006
Johns Hopkins reopens the field
Roland Griffiths and colleagues publish a landmark study of psilocybin and mystical-type experience, restarting mainstream research.
Later scholarly interpretation - 2018–2019
FDA Breakthrough Therapy
The FDA grants Breakthrough Therapy designation to psilocybin programmes for depression, accelerating clinical development.
Later scholarly interpretation - 2025–2026
Phase 3 results
COMPASS Pathways reports positive Phase 3 topline results for treatment-resistant depression, with a regulatory submission targeted for late 2026.
Newly documented
Evidence
The support for this entry, separated by kind. Different kinds of evidence carry different weight.
- Later scholarly interpretation
- Peer-reviewed clinical trials from Johns Hopkins, Imperial College London, NYU and others since 2006.
- Later scholarly interpretation
- Regulatory milestones (FDA Breakthrough Therapy; Phase 3 programmes) — real progress, not yet an approval.
What remains uncertain
- As of 2026 no psilocybin medicine has full FDA approval; Phase 3 results are promising but the regulatory process is unfinished.
- Trial 'blinding' is genuinely hard with a drug people can obviously feel, and long-term and real-world outcomes are still being established.
- Clinical efficacy is a separate question from the traditional and spiritual claims documented elsewhere on this site.
Sources & further reading
Walter N. Pahnke (1963). Drugs and Mysticism (the "Good Friday" / Marsh Chapel Experiment). Harvard University (doctoral dissertation).
The 1962 double-blind study of psilocybin and religious experience — an early attempt at rigour, later criticised for follow-up and safety reporting.
Roland R. Griffiths & and colleagues (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning. Psychopharmacology.
The Johns Hopkins study widely credited with reopening rigorous clinical psilocybin research in the 2000s.
COMPASS Pathways (2025–2026). COMP360 psilocybin Phase 3 programme (COMP005, COMP006) topline results. COMPASS Pathways / Psychiatric Times.
Two Phase 3 trials for treatment-resistant depression reported positive primary endpoints (June 2025, Feb 2026); an NDA submission was targeted for late 2026. Promising, but not yet an approval.
Michael Pollan (2018). How to Change Your Mind. Penguin Press.
The bestseller that re-popularised psychedelic science for a mainstream audience and helped frame the "renaissance" narrative.
Editorial record
Corrections history
No corrections recorded yet. Spotted an error or a mischaracterisation? See how corrections work.
Last reviewed